Journal article
EE542 Assessment of the Cost-Effectiveness of Risk Factor Guided Prophylaxis with Palivizumab for the Prevention of Severe Respiratory Syncytial Virus Infection in Colombian Infants Born at 32–35 Weeks’ Gestational Age
Authors
Rodriguez-Martinez CE; Ordonez J; Carbonell-Estrany X; Fullarton J; Keary I; Rodgers-Gray B; D'Apremont I; Espinosa SM; Ribeiro PA; Stein R
Journal
Value in Health, Vol. 26, No. 12,
Publisher
Elsevier
Publication Date
December 2023
DOI
10.1016/j.jval.2023.09.807
ISSN
1098-3015